Posted by Michael Wonder on 02 Dec 2021
MHRA grants conditional marketing authorisation for COVID-19 treatment Xevudy (sotrovimab)
2 December 2021 - A supply agreement reached with UK government will enable access to sotrovimab for UK patients.
GlaxoSmithKline and Vir Biotechnology today announced that the UK Medicines and Healthcare products Regulatory Agency has granted a conditional marketing authorisation for Xevudy (sotrovimab) for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection.
